Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma

Abstract

Methods: Thirty patients were treated with three cycles of carboplatin (AUC6) plus taxol (175mg/m 2 ) on day 1 every 3 weeks, followed by weekly carboplatin (AUC1) plus Taxol (60mg/m2) and concomitant radiotherapy (70Gy). Results:We observed the objective complete response rates of 33% (after chemotherapy) and 87%(after chemo-radiotherapy). Treatment tolerability and toxicity were controllable. Three and five years progression free survival were 80% and 75% respectively and 3 and 5 years overall survival were 85% and 80% (follow-up 49.5 months). Five years loco-regional control was 90.3% and five years distant metastases free survival was 85%.Conclusions: Neoadjuvant-chemotherapy with such protocol represents a feasible, efficient treatment for patients with A-NPC, ensuring excellent locoregional disease control and overall survival with low incidence of distant metastases.

The efficacy and toxicities of intensive induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with N3 disease

“…The 3-year PFS, DMFS, LRFS and OS were 81.8%, 81.8%, 100%, and 90.9%, respectively. These results compare favorably with previous reports on three cycles ICT including two-drug and three-drug scheme 18,23–25 .We postulate 3 reasons for the exciting results. First, Taxanes-based ICT regime is superior to the PF regimen.…”

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

“…CCRT has been established as the standard of care for advanced NPC, but recently, the addition of neoadjuvant chemotherapy (NACT) to the previously established regimen has been found to be an attractive multidisciplinary approach. Now, evidence supporting the use of NACT prior to definitive CCRT is increasing, and this approach is associated with decreased risks of distant metastases, translating to improved clinical outcomes (5)(6)(7)(8)(9)(10)(11). Despite the survival benefit obtained from modern treatment modalities and techniques, 20%-30% of patients die due to distant and/or loco-regional relapse (12).…”

Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies

“…Italian investigators used the same treatment schedule in 40 patients and obtained an overall response rate of 100% and a 5-year disease-free survival of 77% [24] . In another Italian phase Ⅱ study, Ferrari et al [25] treated thirty-four patients with three cycles of neoadjuvant cisplatin and 5-fluorouracil followed by concurrent cisplatin and RT.…”